Evaluation of kidney toxicity in HIV patients with tenofovir-based regimen: the role of boosted protease inhibitor in real clinical setting by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Evaluation of kidney toxicity in HIV patients with tenofovir-based 
regimen: the role of boosted protease inhibitor in real clinical 
setting
F Ortu*, P Piano, P Serra, R Meleddu, N Corso and PE Manconi
Address: Azienda Ospedaliero Universitaria di Cagliari, Monserrato, Italy
* Corresponding author    
Purpose of the study
Tenofovir (TFV) disoproxil fumarate (TDF) is an oral pro-
drug of the nucleotide reverse transcriptase inhibitor TFV.
Following oral administration, TDF undergoes rapid con-
version to TFV in plasma. TFV is eliminated from systemic
circulation renally through a combination of glomerular
filtration and active tubular secretion. Active tubular
secretion of TFV has been inferred from the observation
that TFV renal clearance exceeds that of creatinine clear-
ance in patients. Renal drug-drug interactions may occur
between therapeutics that are substrates for the same
tubular transport pathways or that inhibit the pathway of
a drug subject to renal excretion: both of them, ritonavir
(RTV) and tenofovir, share the same transport pathways
(MRP4) [Ray et al. Antim Ag Chem 2006 (Oct); 50: 3297–
3304]. The objective of the present study was to investi-
gate in a real clinical setting the relationship between PI/r
co-administration with TDF and changes in estimated
renal function.
Methods
Our study involved 187 patients in TFV-based regimen: 49
in NNRTI and 138 with PI/r. In a follow-up of one year,
we evaluated renal function by calculated glomerular fil-
trate using the Cockcroft-Gault (C-G) equation and the
unabbreviated Modification of Diet in Renal Disease
(MDRD) equation.
Results
The mean baseline renal function was within the normal
range and was similar between treatment groups. In uni-
variate analysis, decreases in C-G estimates of CrCl were
not significantly different among the two groups during
the first 12 months of therapy.
Conclusion
In conclusion, our study demonstrated that also in real-
life conditions, patients receiving TDF in combination
with PI/r-based regimens had greater declines in renal
function than did TDF NNRTI.
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